Despite this, it contradicts the therapeutic purpose of IL12B-targeting monoclonal antibody ustekinumab in treating psoriasis and psoriatic arthritis by reducing IL12B signaling [58]. This evidence concerns the gene IL12B and psoriatic arthritis.